JNJ

225.99

+0.78%↑

UNH

363.44

-1.74%↓

TMO

468.75

+1.08%↑

ISRG

451.32

+0.19%↑

ABT

87.64

+0.15%↑

JNJ

225.99

+0.78%↑

UNH

363.44

-1.74%↓

TMO

468.75

+1.08%↑

ISRG

451.32

+0.19%↑

ABT

87.64

+0.15%↑

JNJ

225.99

+0.78%↑

UNH

363.44

-1.74%↓

TMO

468.75

+1.08%↑

ISRG

451.32

+0.19%↑

ABT

87.64

+0.15%↑

JNJ

225.99

+0.78%↑

UNH

363.44

-1.74%↓

TMO

468.75

+1.08%↑

ISRG

451.32

+0.19%↑

ABT

87.64

+0.15%↑

JNJ

225.99

+0.78%↑

UNH

363.44

-1.74%↓

TMO

468.75

+1.08%↑

ISRG

451.32

+0.19%↑

ABT

87.64

+0.15%↑

Home・Aandelen Lijst・Schrodinger Inc

Search

Schrodinger Inc

Open

SectorGezondheidszorg

12.7 -2.01

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

12.58

Max

13.04

Belangrijke statistieken
By Trading Economics
Inkomsten	169M 136M
Verkoop	33M 87M
EPS	-0.18
Winstmarge	155.644
Werknemers	850
EBITDA	67M 36M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+47.3% upside

Dividenden
By Dow Jones
Volgende Winsten	5 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	40M 867M
Vorige openingsprijs	14.71
Vorige sluitingsprijs	12.7

Nieuwssentiment

By Acuity

43%

57%

155 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

23.27 / 26.13 Steun & Weerstand

Schrodinger Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 mei 2026, 22:17 UTC

Winsten

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4 mei 2026, 23:47 UTC

Winsten

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4 mei 2026, 23:45 UTC

Winsten

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4 mei 2026, 23:45 UTC

Winsten

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4 mei 2026, 23:40 UTC

Marktinformatie

Gold Steady Amid Likely Technical Recovery -- Market Talk

4 mei 2026, 22:44 UTC

Acquisities, Fusies, Overnames

Regis: Jim Beyer To Be Chief Executive of Combined Company

4 mei 2026, 22:43 UTC

Acquisities, Fusies, Overnames

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4 mei 2026, 22:42 UTC

Acquisities, Fusies, Overnames

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4 mei 2026, 22:42 UTC

Acquisities, Fusies, Overnames

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4 mei 2026, 22:41 UTC

Acquisities, Fusies, Overnames

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4 mei 2026, 22:41 UTC

Acquisities, Fusies, Overnames

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4 mei 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Regis: Shareholders to Own About 51% of Combined Company

4 mei 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Regis: Board Unanimously Endorsed, Supported Deal

4 mei 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Regis: Deal Unanimously Recommended by Vault Board

4 mei 2026, 22:39 UTC

Acquisities, Fusies, Overnames

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4 mei 2026, 22:38 UTC

Acquisities, Fusies, Overnames

Regis Resources to Acquire All Ordinary Shares in Vault

4 mei 2026, 22:38 UTC

Acquisities, Fusies, Overnames

Regis Resources, Vault Minerals Agree to Merger of Equals

4 mei 2026, 22:37 UTC

Winsten

Acquisities, Fusies, Overnames

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4 mei 2026, 22:26 UTC

Winsten

Acquisities, Fusies, Overnames

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4 mei 2026, 22:02 UTC

Winsten

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4 mei 2026, 22:00 UTC

Marktinformatie

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4 mei 2026, 21:52 UTC

Winsten

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4 mei 2026, 21:50 UTC

Winsten

Westpac: Some Sectors More Affected Than Others>WBC.AU

4 mei 2026, 21:50 UTC

Winsten

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4 mei 2026, 21:49 UTC

Winsten

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4 mei 2026, 21:44 UTC

Winsten

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4 mei 2026, 21:44 UTC

Winsten

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4 mei 2026, 21:43 UTC

Winsten

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4 mei 2026, 21:41 UTC

Winsten

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4 mei 2026, 21:40 UTC

Winsten

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Peer Vergelijking

Prijswijziging

Schrodinger Inc Prognose

Koersdoel

By TipRanks

47.3% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 18.25 USD 47.3%

Hoogste 20 USD

Laagste 13 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Schrodinger Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

4

Buy

1

Hold

0

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Schrodinger Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

23.27 / 26.13Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bullish.

Sentiment

By Acuity

155 / 347 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Andere aandelen uit de sector

JNJ

Johnson and Johnson

225.99

UNH

UnitedHealth Group Inc

363.44

TMO

Thermo Fisher Scientific Inc

468.75

ISRG

Intuitive Surgical Inc

451.32

ABT

Abbott Laboratories

87.64

Live chat